Vir Biotechnology (VIR) News Today $5.04 -0.20 (-3.73%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VIR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Vir Biotechnology, Inc. $VIR Shares Bought by Charles Schwab Investment Management Inc.August 28 at 3:13 AM | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by BrokeragesAugust 28 at 3:10 AM | marketbeat.comMicron initiated, Eli Lilly upgraded: Wall Street's top analyst callsAugust 27 at 10:51 AM | finance.yahoo.comBofA upgrades Vir Biotechnology to Buy on underappreciated HDV opportunityAugust 27 at 10:51 AM | msn.comVir Biotechnology upgraded to Buy from Neutral at BofAAugust 27 at 10:51 AM | msn.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from AnalystsAugust 26 at 3:11 AM | americanbankingnews.comVanguard Group Inc. Sells 323,127 Shares of Vir Biotechnology, Inc. $VIRAugust 26 at 3:04 AM | marketbeat.comVir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceAugust 25 at 4:05 PM | businesswire.comAberdeen Group plc Acquires 330,031 Shares of Vir Biotechnology, Inc. $VIRAugust 23, 2025 | marketbeat.comVir Biotechnology, Inc. $VIR Shares Bought by Public Sector Pension Investment BoardAugust 23, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by Tejara Capital LtdAugust 17, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for VIR EarningsAugust 12, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Reaches New 12-Month Low - Here's WhyAugust 10, 2025 | marketbeat.comRaymond James Sticks to Its Buy Rating for Vir Biotechnology (VIR)August 9, 2025 | theglobeandmail.comVir Biotechnology (NASDAQ:VIR) Trading Down 11.1% Following Weak EarningsAugust 8, 2025 | marketbeat.comVir Biotechnology Reports Q2 2025 Financial ResultsAugust 7, 2025 | msn.comVir Biotechnology outlines global patient recruitment and cash runway through mid-2027 amid hepatitis delta pipeline momentumAugust 7, 2025 | msn.comVir (VIR) Q2 Revenue Drops 61%August 7, 2025 | fool.comVir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comVir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 6, 2025 | businesswire.comVir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis DeltaAugust 6, 2025 | businesswire.comVir Biotechnology, Inc. (NASDAQ:VIR) Director Sells $109,780.00 in StockAugust 5, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from BrokeragesAugust 1, 2025 | marketbeat.comVir Biotechnology (VIR) Projected to Post Quarterly Earnings on WednesdayJuly 31, 2025 | marketbeat.comVir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis DeltaJuly 31, 2025 | businesswire.comAllianz Asset Management GmbH Has $2 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)July 31, 2025 | marketbeat.comVictory Capital Management Inc. Has $1.12 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)July 31, 2025 | marketbeat.comFirst subject dosed in Phase I trial of Vir Biotechnology’s VIR-5525July 25, 2025 | finance.yahoo.comVir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid TumorsJuly 24, 2025 | businesswire.comVir Biotechnology: Hep B And Cancer Projects March OnJuly 23, 2025 | seekingalpha.comVir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025July 22, 2025 | businesswire.comVir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $19,615.42 in StockJuly 18, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $37,174.12 in StockJuly 18, 2025 | marketbeat.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells 3,586 Shares of StockJuly 18, 2025 | insidertrades.comInvenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory BoardJuly 14, 2025 | finance.yahoo.comRaymond James Initiates Coverage of Vir Biotechnology (VIR) with Outperform RecommendationJuly 12, 2025 | msn.comVir Biotechnology (NASDAQ:VIR) Now Covered by Analysts at Raymond James FinancialJuly 11, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading Up 9.2% - What's Next?July 9, 2025 | marketbeat.comVicki L. Sato Sells 22,000 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) StockJuly 3, 2025 | insidertrades.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 22,000 Shares of StockJuly 2, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by State of Alaska Department of RevenueJune 30, 2025 | marketbeat.comIs Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?June 25, 2025 | finance.yahoo.comBank of America Corp DE Has $1.42 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)June 6, 2025 | marketbeat.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 3,200 Shares of StockJune 3, 2025 | marketbeat.comJanet Napolitano Sells 3,200 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) StockJune 3, 2025 | insidertrades.comNuveen Asset Management LLC Has $2.64 Million Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)June 3, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Stock Price Down 7.6% - Here's What HappenedMay 31, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading 6.6% Higher - What's Next?May 30, 2025 | marketbeat.comVir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and OncologyMay 29, 2025 | investing.comVir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025May 28, 2025 | businesswire.com Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VIR Media Mentions By Week VIR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIR News Sentiment▼0.980.99▲Average Medical News Sentiment VIR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIR Articles This Week▼125▲VIR Articles Average Week Get the Latest News and Ratings for VIR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Vir Biotechnology and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies KNSA News OGN News TARS News CNTA News DNLI News AGIO News IDYA News IBRX News HRMY News RXRX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIR) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access